#USA #Boston #radiopharmaceuticals #Ratio Therapeutics #RayzeBio

Ratio Therapeutics Collaborates with RayzeBio

In a significant development for cancer treatment, Ratio Therapeutics Inc. has announced a collaboration with RayzeBio, Inc. This partnership focuses on advancing a groundbreaking radiopharmaceutical program aimed at addressing cancer's complexity and improving therapeutic outcomes for patients.

Partnership Details

The collaboration brings together the innovative expertise of Ratio, a pharmaceutical company renowned for developing top-tier radiopharmaceuticals, and RayzeBio, a clinical-stage organization dedicated to transforming lives through innovative cancer therapies. This partnership aims to develop a next-generation radiopharmaceutical candidate focusing on two undisclosed therapeutic targets, which could potentially revolutionize tumor targeting in cancer treatment.

Under the agreement, Ratio will initially receive an upfront payment. In addition, they will be eligible for development, regulatory, and commercial milestone payments, as well as royalties on net sales from products developed through this initiative. Both companies will utilize their unique strengths, combining Ratio's prowess in discovery and translation with RayzeBio's expertise in radiopharmaceuticals, creating a synergistic effort toward advancing cancer therapies.

The Vision Behind the Collaboration

Jack Hoppin, CEO of Ratio, expressed pride in collaborating with RayzeBio, highlighting the complementary scientific expertise both teams bring to the table. He believes that their combined efforts create an opportunity to develop a potentially differentiated therapeutic candidate that enhances tumor targeting and therapeutic efficacy, ultimately delivering significant benefits for cancer patients.

Similarly, Ben Hickey, President of RayzeBio, remarked on the exciting possibilities this partnership presents. He envisions exploring radiopharmaceutical innovations that tackle the complexity and heterogeneity of cancer effectively. By integrating their respective technologies and development processes, this collaboration is positioned to produce a novel therapeutic candidate with advanced precision in tumor targeting.

Background on Ratio Therapeutics

Ratio Therapeutics is a clinical-stage company headquartered in Boston, focused on developing next-generation precision radiopharmaceuticals intended to transform oncology treatment approaches. The company employs a talented team of experts across various disciplines in radiopharmaceutical discovery and development. Notably, Ratio utilizes proprietary platforms such as Trillium™ and Macropa™ for creating fit-for-purpose radiopharmaceuticals that improve both therapeutic and imaging capabilities, ensuring optimal drug delivery and efficacy.

Additionally, Ratio is committed to maintaining a hybrid manufacturing strategy, employing both contract development and manufacturing organizations (CDMOs) and their own advanced facilities in Salt Lake City, Utah, to ensure the highest quality and reliability in radiopharmaceutical production.

Future Implications

As the collaboration progresses, both Ratio and RayzeBio anticipate that this synergistic relationship will pave the way for innovative approaches to improving cancer therapies. By enhancing tumor targeting and retention capacities, they aim to offer new solutions that could significantly expand therapeutic options available to patients battling cancer. This partnership exemplifies the potential of collaboration within the pharmaceutical industry to advance healthcare and improve patient outcomes.

For further information about Ratio Therapeutics and their collaborations, visit their official website at Ratio Therapeutics.